source
- Setara Biosciences raises $90M Series A to advance neuroscience pipeline after Jazz's $820M Actio acquisitionJazz Pharmaceuticals completed an $820 million purchase of Actio Biosciences in September, creating a new spinout called Setara Biosciences to house the remaining drug programs. Setara has secured…
- Delays in reaching clinical proof-of-concept can dramatically increase biotech cash burnThe article explains how the timing of achieving clinical proof‑of‑concept (POC) directly affects a biotech company's cash consumption. While a study’s cost is important, the ongoing expenses of st…